Holen Sie sich die Stockscreener-App
262.14
2.16%
-5.785
Illumina Inc Aktie (ILMN) Neueste Nachrichten
TD Cowen lifts target for Illumina stock to USD 270.00 - ad-hoc-news.de
Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million - GlobeNewswire Inc.
$100 Invested In Illumina 15 Years Ago Would Be Worth This Much Today - Benzinga
Illumina Debuts BioInsight Platform, Expands AI Tools for Genomic Research - marketscreener.com
Illumina Consolidates Data Analysis Products Into New Platform, Pricing Model - GenomeWeb
Press Release - Illumina
Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs - PR Newswire
Illumina, Inc. (ILMN) Launches BioInsight Platform With DRAGEN v4.6 - TradingView
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? - Zacks Investment Research
Did Illumina’s (ILMN) New SpliceAI2 Genomic Model Just Reframe Its Clinical Genomics Narrative? - Yahoo Finance
Illumina Launches $1.0 Billion Unsecured Commercial Paper Program; Signs Dealer Agreements - TradingView
Illumina Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Illumina Earnings Preview: What to Expect - Barchart.com
Should Invesco S&P MidCap Quality ETF (XMHQ) Be on Your Investing Radar? - Zacks Investment Research
Illumina’s (ILMN) Sequencing Business Is Recovering, But Is the Stock Getting Ahead of Itself? - Yahoo Finance
Introducing SpliceAI2: The Next Generation of Splicing and Transcript Isoform Prediction - Illumina
Illumina Inc (ILMN) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 65/100 - GuruFocus
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina, Inc. Stock 12‑Month Price Target Raised to $237.16, Implies 10% Downside - TradingView
What is Illumina’s (ILMN) Economic Moat, and is it Widening or Narrowing? - Yahoo Finance
Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - Investing News Network
Illumina, Inc. Initiates Recall of NovaSeq 6000Dx Including DRAGEN Server And Illumina DRAGEN Server For NextSeq 550Dx - www.marketscreener.com
Illumina Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - Illumina
Illumina releases SpliceAI2 to help advance rare disease research - Illumina
Illumina releases SpliceAI2 to help advance rare disease research - PR Newswire
After shares were delivered or withheld for exercise price or tax liability, Illumina (ILMN) CEO holds 107,770 shares. - Stock Titan
Illumina Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
She transformed genomics. Multiomics is next: The Sequence - Illumina
With voting power over 15.4M shares, FMR reports a passive stake in Illumina (ILMN). - Stock Titan
Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.
RBC raises target for Illumina stock to USD 310 - AD HOC NEWS
Illumina (ILMN) Shares Skyrocket, What You Need To Know - Yahoo Finance
Illumina (ILMN) Shares Skyrocket, What You Need To Know - FinancialContent
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina stock gains 7.95 percent as RBC raises target - AD HOC NEWS
Illumina Inc Stock (ILMN) Moved Up by 7.85% on Oct 5: Drivers Behind the Movement - TradingKey
Illumina rises as recent analyst target hikes and index inclusion keep momentum intact - Quiver Quantitative
Illumina stock hits 52-week high at 280.44 USD By Investing.com - Investing.com South Africa
Illumina stock hits 52-week high at 280.44 USD - Investing.com
Illumina's Clinical Sequencing Revenue Seen as Durable Mid-Teens Grower, RBC Capital Markets Says - marketscreener.com
Illumina's Clinical Sequencing Revenue Seen as Durable Mid-Teens Grower, RBC Capital Markets Says - Yahoo Finance
RBC Capital raises Illumina stock price target on clinical sales - Investing.com
RBC Capital maintains Outperform rating on Illumina, $310 price target - TradingView
RBC raises target for Illumina stock to USD 310 - AD HOC NEWS
Illumina Inc : RBC Raises Target Price to $31 - Moomoo
Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR - GlobeNewswire Inc.
Form 4 Illumina Inc For: 2 October By Investing.com - Investing.com South Africa
A director receives 107 shares instead of cash for quarterly retainer fees at Illumina (ILMN). - Stock Titan
A director receives stock for 100% of Q3 retainer fees at Illumina (ILMN) - Stock Titan
2.34%
2.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):